Earli is a technology company.
Earli has raised $60.0M across 2 funding rounds.
Earli has raised $60.0M in total across 2 funding rounds.
Earli Inc. is a biotech company developing a "synthetic biopsy" platform to enable ultra-early cancer detection and treatment by reprogramming cancer cells to produce detectable biomarkers or self-destruct.[1][2][3][5] It serves cancer patients and clinicians, solving the critical challenge of distinguishing malignant from normal growth at the earliest stages, when intervention is most effective—addressing a problem highlighted as one of humanity's greatest scientific hurdles.[1][3][5] Founded in 2018, Earli has raised over $60 million in funding, advanced to clinical trials rapidly, and partnered with firms like Accenture Ventures to scale its intersection of biology, engineering, and software.[2][3][4]
Earli was co-founded in June 2018 by entrepreneur Cyriac Roeding, the late Stanford professor Sam Gambhir, and Dr. David Suhy as Chief Scientific Officer.[1][3] Roeding, who sold his mobile app Shopkick for $250 million, became fascinated by Gambhir's research at Stanford's Canary Center on early cancer detection after reading about it amid personal connections to cancer; he couldn't shake the idea despite trying.[1][3] After nine months screening hundreds of candidates, they recruited Suhy, a gene therapy expert with 20 years of experience advancing products to Phase 2 trials.[1] The team quickly moved into a South San Francisco lab and spent five years building a platform to answer "Is it cancer? Y/N" by encoding proteins in cancer cells, licensed from Stanford tech.[1][2]
Earli stands out in oncology through its synthetic biopsy platform, which uses programmable genetic constructs activated only in cancer cells to force biomarker production for precise, localizable detection via non-invasive methods like blood or PET scans—or even self-destruction therapies.[1][2][3][5] Key strengths include:
Earli rides the wave of synthetic biology and precision oncology, merging gene therapy, AI-driven patient data, and machine learning to tackle early detection—a gap where most cancers are found too late.[2][3][5] Timing aligns with surging investments in techbio (e.g., $40M Series A in 2018-2020s, Accenture partnership in 2024), fueled by market forces like aging populations, rising cancer rates, and post-COVID demand for non-invasive diagnostics.[2][3] It influences the ecosystem by shifting the "cancer playbook" toward proactive, localized interventions, inspiring similar platforms and accelerating clinical translation through Silicon Valley's blend of academia (Stanford) and venture capital.[1][2][3]
Earli is poised to redefine cancer care by scaling its platform across oncology indications, with clinical trials underway and aspirations for broader gene control to treat diverse diseases.[1][2][4] Trends like AI-enhanced biomarkers, radioligand therapies, and global early-detection mandates will propel it, potentially yielding FDA approvals and partnerships with pharma giants. Its influence may evolve from detection pioneer to full-spectrum curative force, fulfilling the mission to make cancer "benign" through relentless innovation at biology-engineering's edge—echoing the high-level quest to unbraid malignancy from normalcy.[1][3][5]
Earli has raised $60.0M in total across 2 funding rounds.
Earli's investors include Abstract Ventures, Afore Capital, Alsop Louie Partners, Altimeter Capital, Andreessen Horowitz, ARCH Venture Partners, Better Tomorrow Ventures, Core Innnovation Capital, DFJ Growth, Dragoneer Investment Group, DST Global, First Round Capital.
Earli has raised $60.0M across 2 funding rounds. Most recently, it raised $40.0M Series A in January 2021.